Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding Toxoplasma gondii ROP18

Vaccine

Volumn 29, Issue 38, 2011, Pages 6614-6619

  Yuan, Zi Guo ^a,b   Zhang, Xiu Xiang ^b   Lin, Rui Qing ^a,b   Petersen, Eskild ^c   He, Shenyi ^d   Yu, Miao ^e   He, Xian Hui ^b   Zhou, Dong Hui ^a   He, Yong ^b   Li, Hao Xin ^b   Liao, Ming ^b   Zhu, Xing Quan ^a,f,g  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

^c AARHUS UNIVERSITY   (Denmark)

^d SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e STOMATOLOGY HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY   (China)

^f YUNNAN AGRICULTURAL UNIVERSITY   (China)

^g HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY   (China)

Author keywords

Immunity, Vaccine; Rhoptry protein 18; Toxoplasma gondii; Toxoplasmosis

Indexed keywords

CD69 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PROTOZOAL PROTEIN; PVAX ROP18 VACCINE; TOXOPLASMA GONDII VACCINE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; EXPRESSION VECTOR; FEMALE; GENE INSERTION; GENE SEQUENCE; GENETIC CODE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE VIRULENCE; PRIORITY JOURNAL; SURVIVAL TIME; TH1 CELL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; ANTIBODIES, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; PROTEIN-SERINE-THREONINE KINASES; PROTOZOAN VACCINES; RODENT DISEASES; SURVIVAL ANALYSIS; TOXOPLASMOSIS, ANIMAL; VACCINATION; VACCINES, DNA;

EID: 80051667014     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.110     Document Type: Article

References (32)

1. Kravetz J.D., Federman D.G. Toxoplasmosis in pregnancy. Am J Med 2005, 118(3):212-216.
2. Frenkel J.K., Escajadillo A. Cyst repture as a pathogenic mechanism of toxoplasmic encephalitis. Am J Trop Med Hyg 1987, 36(3):517-522.
3. Luft G.J., Remington J.S. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992, 15(2):211-222.
4. Bhopale G.M. Development of a vaccine for toxoplasmosis: current status. Microbes Infect 2003, 5(5):457-462.
5. Jongert E., Roberts C.W., Gargano N., Förster-Wald E., Petersen E. Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz 2009, 104:252-266.
6. Robinson H.L. DNA vaccines: basic mechanism and immune responses. Int J Mol Med 1999, 4(5):549-555.
7. Gurunathan S., Klinman D., Seder R.A. DNA vaccines: immunology, application and optimization. Annu Rev Immunol 2000, 18:927-974.
8. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu Rev Immunol 1997, 15:617-648.
9. Taylor S., Barragan A., Su C., Fux B., Fentress S., Tang K., et al. A secreted serine-threonine kinase determines virulence in the eukaryotic pathogen Toxoplasma gondii. Science 2006, 314(5806):1776-1780.
10. Saeij J., Boyle J., Coller S., Taylor S., Sibley L., Brooke-Powell E., et al. Polymorphic secreted kinases are virulence factors in toxoplasmosis. Science 2006, 314(5806):1780-1783.
11. E.I.Hajj H., Lebrun M., Arold S., Vial H., Labesse G., Dubremetz J.F., et al. ROP18 is a rhoptry kinase controlling the intracellular proliferation of Toxoplasma gondii. PLoS Pathog 2007, 3(2):e14.
12. Peng G.H., Yuan Z.G., Zhou D.H., He X.H., Liu M.M., Yan C., et al. Toxoplasma gondii microneme protein 6 (MIC6) is a potential vaccine candidate against toxoplasmosis in mice. Vaccine 2009, 27(47):6570-6574.
13. Bounous D.I., Campagnoli R.P., Brown J. Comparison of MTT colorimetric assay and tritiated thymidine uptake for lymphocyte proliferation assays using chicken splenocytes. Avian Dis 1992, 36(4):1022-1027.
14. Shang L., Liu Q., Liu W., Men J., Gao S., Jiang L., et al. Protection in mice immunized with a heterologous prime-boost regime using DNA and recombinant pseudorabies expressing TgSAG1 against Toxoplasma gondii challenge. Vaccine 2009, 27(21):2741-2745.
15. Zhang X., Yuan Z., Duan Q., Zhu H., Yu H., Wang Q. Mucosal immunity in mice induced by orally administered transgenic rice. Vaccine 2009, 27(10):1596-1600.
16. Sharma A.K., Khuller G.K. DNA vaccines: future strategies and relevance to intracellular pathogens. Immunol Cell Biol 2001, 79(6):537-546.
17. Stanley S.L. Vaccines for amoebiasis: barriers and opportunities. Parasitology 2006, 133(Suppl.):S81-S86.
18. Perkins M.E. Rhoptry organelles of apicomplexan parasites. Parasitol Today 1992, 8(1):28-32.
19. Nichols B.A., Chiappino M.L., O'Connor G.R. Secretion from the rhoptries of Toxoplasma gondii during host-cell invasion. J Ultrastruct Res 1983, 83(1):85-98.
20. Denkers E.Y., Gazzinelli R.T. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 1998, 11(4):569-588.
21. Montoya J.G., Lowe K.E., Clayberger C., Moody D., Do D., Remingtong J.S., et al. Human CD4+ and CD8+ T lymphocytes are both cytotoxic to Toxoplasma gondii-infected cells. Infect Immun 1996, 64(1):176-181.
22. Liu C.S., Sun Y., Hu Y.H., Sun L. Identification and analysis of a CpG motif that protects turbot (Scophthalmus maximus) against bacterial challenge and enhances vaccine-induced specific immunity. Vaccine 2010, 28(25):4153-4161.
23. Corral R.S., Petray P.B. CpG DNA as a Th1-promoting adjuvant in immunization against Tyrpanosoma cruzi. Vaccine 2000, 19(2-3):234-242.
24. Yuan Z., Zhang S., Liu Y., Zhang F., Fooks A.R., Li Q., et al. A recombinant pseudorabies virus expressing rabies virus glycoprotein: safety and immunogenicity in dogs. Vaccine 2008, 26(10):1314-1321.
25. Hu R., Zhang S., Fooks A.R., Yuan H., Liu Y., Li H., et al. Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein. Microbes Infect 2006, 8(4):1090-1097.
26. Paris R.M., Kim J.H., Robb M.L., Michael N.L. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines 2010, 9(9):1055-1069.
27. Boothroyd J.C., Grigg M.E. Population biology of Toxoplasma gondii and its relevance to human infection: do different strains cause different disease?. Curr Opin Microbiol 2002, 5(4):438-442.
28. Howe D.K., Sibley L.D. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J Infect Dis 1995, 172(6):1561-1566.
29. Fuentes I., Rubio J.M., Ramirez C., Alvar J. Genotypic characterization of Toxoplasma gondii strains associated with human toxoplasmosis in Spain: direct analysis from clinical samples. J Clin Microbiol 2001, 39(4):1566-1570.
30. Grigg M.E., Ganatra J., Boothroyd J.C., Margolis T.P. Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J Infect Dis 2001, 184(5):633-639.
31. Khan A., Jordan C., Muccioli C., Vallochi A.L., Rizzo L.V., Belfort R., et al. Genetic divergence of Toxoplasma gondii strains associated with ocular toxoplasmosis. Brazil. Emerg Infect Dis 2006, 12(6):942-949.
32. Khan A., Su C., German M., Storch G.A., Clifford D.B., Sibley L.D. Genotyping of Toxoplasma gondii strains from immunocompromised patients reveals high prevalence of type I strains. J Clin Microbiol 2005, 43(12):5881-5887.